Chapter/Section Purchase

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Narcolepsy Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Central nervous system stimulants
1.2.3 Sodium Oxybate
1.2.4 Selective Serotonin Reuptake Inhibitor (SSRI)
1.2.5 Tricyclic Antidepressants
1.2.6 Others
1.3 Market by Application
1.3.1 Global Narcolepsy Therapeutics Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Narcolepsy With Cataplexy
1.3.3 Narcolepsy Without Cataplexy
1.3.4 Secondary Narcolepsy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Narcolepsy Therapeutics Market Perspective (2018-2032)
2.2 Narcolepsy Therapeutics Growth Trends by Region
2.2.1 Narcolepsy Therapeutics Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Narcolepsy Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Narcolepsy Therapeutics Forecasted Market Size by Region (2023-2032)
2.3 Narcolepsy Therapeutics Market Dynamics
2.3.1 Narcolepsy Therapeutics Industry Trends
2.3.2 Narcolepsy Therapeutics Market Drivers
2.3.3 Narcolepsy Therapeutics Market Challenges
2.3.4 Narcolepsy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Narcolepsy Therapeutics Players by Revenue
3.1.1 Global Top Narcolepsy Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Narcolepsy Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Narcolepsy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Narcolepsy Therapeutics Revenue
3.4 Global Narcolepsy Therapeutics Market Concentration Ratio
3.4.1 Global Narcolepsy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Narcolepsy Therapeutics Revenue in 2022
3.5 Narcolepsy Therapeutics Key Players Head office and Area Served
3.6 Key Players Narcolepsy Therapeutics Product Solution and Service
3.7 Date of Enter into Narcolepsy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Narcolepsy Therapeutics Breakdown Data by Type
4.1 Global Narcolepsy Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Narcolepsy Therapeutics Forecasted Market Size by Type (2023-2032)
5 Narcolepsy Therapeutics Breakdown Data by Application
5.1 Global Narcolepsy Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Narcolepsy Therapeutics Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Narcolepsy Therapeutics Market Size (2018-2032)
6.2 North America Narcolepsy Therapeutics Market Size by Country (2018-2023)
6.3 North America Narcolepsy Therapeutics Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Narcolepsy Therapeutics Market Size (2018-2032)
7.2 Europe Narcolepsy Therapeutics Market Size by Country (2018-2023)
7.3 Europe Narcolepsy Therapeutics Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Narcolepsy Therapeutics Market Size (2018-2032)
8.2 Asia-Pacific Narcolepsy Therapeutics Market Size by Country (2018-2023)
8.3 Asia-Pacific Narcolepsy Therapeutics Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Narcolepsy Therapeutics Market Size (2018-2032)
9.2 Latin America Narcolepsy Therapeutics Market Size by Country (2018-2023)
9.3 Latin America Narcolepsy Therapeutics Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Narcolepsy Therapeutics Market Size (2018-2032)
10.2 Middle East & Africa Narcolepsy Therapeutics Market Size by Country (2018-2023)
10.3 Middle East & Africa Narcolepsy Therapeutics Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Addrenex Pharmaceuticals, Inc.
11.1.1 Addrenex Pharmaceuticals, Inc. Company Detail
11.1.2 Addrenex Pharmaceuticals, Inc. Business Overview
11.1.3 Addrenex Pharmaceuticals, Inc. Narcolepsy Therapeutics Introduction
11.1.4 Addrenex Pharmaceuticals, Inc. Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.1.5 Addrenex Pharmaceuticals, Inc. Recent Development
11.2 Teva Pharmaceutical Industries Ltd.
11.2.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.2.3 Teva Pharmaceutical Industries Ltd. Narcolepsy Therapeutics Introduction
11.2.4 Teva Pharmaceutical Industries Ltd. Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.2.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.3 Jazz Pharmaceuticals PLC
11.3.1 Jazz Pharmaceuticals PLC Company Detail
11.3.2 Jazz Pharmaceuticals PLC Business Overview
11.3.3 Jazz Pharmaceuticals PLC Narcolepsy Therapeutics Introduction
11.3.4 Jazz Pharmaceuticals PLC Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.3.5 Jazz Pharmaceuticals PLC Recent Development
11.4 Graymark Healthcare, Inc.
11.4.1 Graymark Healthcare, Inc. Company Detail
11.4.2 Graymark Healthcare, Inc. Business Overview
11.4.3 Graymark Healthcare, Inc. Narcolepsy Therapeutics Introduction
11.4.4 Graymark Healthcare, Inc. Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.4.5 Graymark Healthcare, Inc. Recent Development
11.5 Arena Pharmaceuticals, Inc.
11.5.1 Arena Pharmaceuticals, Inc. Company Detail
11.5.2 Arena Pharmaceuticals, Inc. Business Overview
11.5.3 Arena Pharmaceuticals, Inc. Narcolepsy Therapeutics Introduction
11.5.4 Arena Pharmaceuticals, Inc. Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.5.5 Arena Pharmaceuticals, Inc. Recent Development
11.6 BIOPROJET
11.6.1 BIOPROJET Company Detail
11.6.2 BIOPROJET Business Overview
11.6.3 BIOPROJET Narcolepsy Therapeutics Introduction
11.6.4 BIOPROJET Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.6.5 BIOPROJET Recent Development
11.7 Takeda
11.7.1 Takeda Company Detail
11.7.2 Takeda Business Overview
11.7.3 Takeda Narcolepsy Therapeutics Introduction
11.7.4 Takeda Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.7.5 Takeda Recent Development
11.8 Ligand Pharmaceuticals, Inc.
11.8.1 Ligand Pharmaceuticals, Inc. Company Detail
11.8.2 Ligand Pharmaceuticals, Inc. Business Overview
11.8.3 Ligand Pharmaceuticals, Inc. Narcolepsy Therapeutics Introduction
11.8.4 Ligand Pharmaceuticals, Inc. Revenue in Narcolepsy Therapeutics Business (2018-2023)
11.8.5 Ligand Pharmaceuticals, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details